Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2020-03-25 Board/Management Inform…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This document specifically details changes to the company's board of directors, which falls under the category of Board/Management Information (MANG).
2020-03-25 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of a General Shareholders' Meeting (AGM) for '대한약품' (Daehan Pharmaceutical). It details the outcomes of voting on agenda items such as financial statement approval, dividend declarations, and the election of directors and auditors. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2020-03-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document details the changes in share ownership by a company director (Lee Seung-young) of Daehan Pharmaceutical Co., Ltd. due to market purchases. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it tracks insider transactions and changes in beneficial ownership by company executives.
2020-03-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details specific share acquisitions (장내매수) by an executive (이승영) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory disclosure for insider trading/shareholding changes by company directors, which falls under the 'Director's Dealing' category.
2020-03-17 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit), and auditor information. While it contains financial data, it is a summary announcement of the audit results rather than the full 10-K annual report or a standalone audit report document. Given the structure and the nature of the disclosure as a summary of audit findings, it fits best under the 'Audit Report / Information' category. FY 2019
2020-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daihan Pharmaceutical Co., Ltd. It contains the agenda for the 56th Annual General Meeting, including the approval of financial statements, election of directors and auditors, and dividend proposals. It also includes detailed financial statements (balance sheet, income statement, etc.) as reference materials for shareholders. This type of document is a standard Proxy Solicitation & Information Statement used to inform shareholders of meeting details and provide necessary information for voting.
2020-03-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.